Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative bevacizumab plus weekly paclitaxel, carboplatin and metronomic cyclophosphamide ± trastuzumab/endocrine therapy in inflammatory breast cancer
2009-016453-17Phase 2Completed
- Sponsor
- European Institute of Oncology
- Start
- Dec 2009
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab, paclitaxel, carboplatin, cyclophosphamide and trastuzumab in inflammatory breast cancer (IBC), sponsored by European Institute of Oncology. Primary endpoint: Pathological complete remission rate. Started Dec 2009; status: completed.
02
Drugs
03
Conditions
inflammatory breast cancer (IBC)
Beyond the preview
Go deeper on 2009-016453-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016453-17.